Pacira BioSciences (PCRX) Current Deferred Revenue (2010 - 2017)

Pacira BioSciences' Current Deferred Revenue history runs 8 years deep, the most recent figure standing at $102000.0 for Q4 2017.

• On a quarterly basis, Current Deferred Revenue fell 82.86% year-over-year to $102000.0 in Q4 2017; TTM through Dec 2017 was $102000.0, a 82.86% decrease from a year earlier, with the FY2017 full-year figure at $102000.0, down 82.86% from the prior year.
• Current Deferred Revenue slipped to $102000.0 in Q4 2017 per PCRX's latest filing, from $520000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $1.4 million in Q2 2014 and bottomed at $102000.0 in Q4 2017.
• The 5-year median for Current Deferred Revenue is $1.0 million (2013), against an average of $1.1 million.
• Across the five-year window, Current Deferred Revenue slumped 86.56% in 2013 and surged 46.71% in 2014, its largest moves.
• Year by year, Current Deferred Revenue stood at $1.0 million in 2013, then soared by 41.47% to $1.4 million in 2014, then changed by 0.0% to $1.4 million in 2015, then sank by 58.27% to $595000.0 in 2016, then slumped by 82.86% to $102000.0 in 2017.
• Per Business Quant, the three latest PCRX Current Deferred Revenue figures stand at $102000.0 (Q4 2017), $520000.0 (Q1 2017), and $595000.0 (Q4 2016).